Fundamental Analysis of TME PHARMA NV(EPA:ALTME) stock

Fundamental Rating

Overall ALTME gets a fundamental rating of 2 out of 10. We evaluated ALTME against 69 industry peers in the Biotechnology industry. While ALTME seems to be doing ok healthwise, there are quite some concerns on its profitability. ALTME has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALTME has reported negative net income.

In the past year ALTME has reported a negative cash flow from operations.

In the past 5 years ALTME always reported negative net income.

In the past 5 years ALTME always reported negative operating cash flow.

1.2 Ratios

ALTME has a Return On Assets of -214.99%. This is amonst the worse of the industry: ALTME underperforms 88.71% of its industry peers.

ALTME has a worse Return On Equity (-403.64%) than 74.19% of its industry peers.

		Industry Rank	Sector Rank
ROA	-214.99%
ROE	-403.64%
ROIC	N/A

ROA(3y)-235.68%

ROA(5y)-170.9%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALTME so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for ALTME has been increased compared to 1 year ago.

Compared to 5 years ago, ALTME has more shares outstanding

ALTME has a better debt/assets ratio than last year.

2.2 Solvency

ALTME has an Altman-Z score of -95.65. This is a bad value and indicates that ALTME is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of ALTME (-95.65) is worse than 95.16% of its industry peers.

ALTME has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-95.65

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

ALTME has a Current Ratio of 2.11. This indicates that ALTME is financially healthy and has no problem in meeting its short term obligations.

With a Current ratio value of 2.11, ALTME perfoms like the industry average, outperforming 43.55% of the companies in the same industry.

A Quick Ratio of 2.11 indicates that ALTME has no problem at all paying its short term obligations.

ALTME has a Quick ratio (2.11) which is in line with its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.11
Quick Ratio	2.11

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 86.82% over the past year.

EPS 1Y (TTM)86.82%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%89.1%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.24% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y84.85%

EPS Next 2Y25.53%

EPS Next 3Y12.24%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALTME. In the last year negative earnings were reported.

Also next year ALTME is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ALTME's earnings are expected to grow with 12.24% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y25.53%

EPS Next 3Y12.24%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALTME!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TME PHARMA NV

EPA:ALTME (1/3/2025, 7:00:00 PM)

0.07

0 (-4.11%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners1.34%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap6.59M

Analysts86

Price Target0.4 (471.43%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-20.41%

PT rev (3m)-20.41%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)42.31%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	4.21
P/tB	4.22
EV/EBITDA	N/A

EPS(TTM)-0.58

EYN/A

EPS(NY)-0.43

Fwd EYN/A

FCF(TTM)-0.05

FCFYN/A

OCF(TTM)-0.05

OCFYN/A

SpS0

BVpS0.02

TBVpS0.02

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-214.99%
ROE	-403.64%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-235.68%

ROA(5y)-170.9%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	2.31%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.11
Quick Ratio	2.11
Altman-Z	-95.65

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)16.77%

Cap/Depr(5y)31.39%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)86.82%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%89.1%

EPS Next Y84.85%

EPS Next 2Y25.53%

EPS Next 3Y12.24%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y32.73%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year60%

EBIT Next 3Y-24.4%

EBIT Next 5YN/A

FCF growth 1Y59.56%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y59.55%

OCF growth 3YN/A

OCF growth 5YN/A

TME PHARMA NV (ALTME.PA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens